Atea Pharmaceuticals (AVIR) vs Benitec Biopharma (BNTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed Benitec Biopharma (BNTC) over the past year, gaining 33.3% versus a loss of 40.3%. Over five years, AVIR leads with a -51.4% price change compared with -85.7% for BNTC. Atea Pharmaceuticals is the larger company by market cap ($318.0 million vs $285.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | BNTC |
|---|---|---|
| Share price | $3.96 | $7.92 |
| Market cap | $318.00M | $285.88M |
| 1-day change | +0.76% | -2.76% |
| YTD return | +10.92% | -41.24% |
| 1-year return | +33.33% | -40.31% |
| 5-year return | -51.35% | -85.67% |
| EPS (TTM) | $-1.95 | $-1.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-158.35M | $-45.55M |
| 52-week high | $6.45 | $14.39 |
| 52-week low | $2.96 | $7.72 |
| Distance from 52-week high | -38.60% | -45.00% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +127.27% | +200.06% |
| Average volume | 290.60K | 174.01K |
| Shares outstanding | 80.30M | 36.12M |
| Employees | 55 | 24 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed BNTC by 73.6 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees
AVIR vs BNTC FAQ
Which is bigger, Atea Pharmaceuticals or Benitec Biopharma?
Atea Pharmaceuticals (AVIR) is larger, with a market capitalization of $318.00M compared with $285.88M for Benitec Biopharma (BNTC).
Which stock has performed better over the past year, AVIR or BNTC?
AVIR returned +33.33% over the past 12 months, compared with -40.31% for BNTC (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and Benitec Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.